Czech patients with mild form of Alzheimer's disease could get breakthrough treatment in 2026

Czech patients with a mild form of Alzheimer's disease could get breakthrough treatment, that should slow the progression of the disease, early next year. The first drug of its kind in Europe, containing  lecanemab, was approved by the European Commission last week and the Japanese firm behind it, Eisai, plans to offer it to patients in the Czech Republic, among others. Deputy health minister, Jakub Dvořáček, said the Czech health authorities are now selecting centres where the drug could be administered and are working to prepare doctors and patients for it. More details, including the price of the treatment and its reimbursement from health insurance, should be made public by the end of the year.